Based on our results, we demonstrate for the first time that LILRB1 is a viable target for immunotherapy and propose LILRB1 CAR-T cells as a prototype for a novel strategy applicable across various hematologic malignancies. The gene discussed is LILRB1; the disease is hematologic disorder.